Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation

Xiaoyan Xu, Tingxue Xie, Mengxin Zhou, Yaqin Sun, Fengqi Wang, Yanan Tian, Ziyan Chen, Yanqi Xie, Ronghai Wu, Xufeng Cen, Jichun Zhou, Tingjun Hou, Lei Zhang, Chaoyang Huang, Qingwei Zhao, Dongrui Wang, Hongguang XiaNature Communications 2024 · DOI

This study, published in Nature Communications, identifies the chaperone protein Hsc70 as a key regulator of PD-L1 stability. By competing with the recycling protein CMTM6, Hsc70 targets PD-L1 for degradation via the endosome-lysosome pathway, effectively boosting anti-tumor immunity and offering a potential strategy to overcome resistance to current immunotherapies.

TL;DR

Researchers have discovered that the chaperone protein Hsc70 acts as a "molecular executioner" for PD-L1, dragging it to the lysosome for destruction via endosomal microautophagy. By boosting Hsc70 levels—either genetically or using the drug AUY-922—scientists were able to shrink tumors and enhance the effectiveness of existing immune checkpoint inhibitors in mouse models.

What Problem Does This Paper Address?

Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have revolutionized oncology, but they aren't a silver bullet. Many patients develop resistance, often because PD-L1 is a moving target. When an antibody binds to PD-L1 on a tumor cell, the protein is often internalized into the cell. Instead of being destroyed, it is frequently stored in "recycling endosomes" and shuttled back to the cell surface by a protein called CMTM6.

This recycling loop keeps the "don't eat me" signal active on the tumor surface, even in the presence of drugs. The authors sought to find a way to break this loop by identifying the molecular machinery that can divert PD-L1 away from recycling and toward the lysosome for permanent degradation.

Methods

The team employed a multi-disciplinary approach to map the PD-L1 lifecycle:

  • Proteomics: They used liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify proteins that physically interact with PD-L1, leading them to Hsc70 (HSPA8).
  • Functional Assays: Using siRNA knockdown and CRISPR-mediated overexpression in breast cancer (4T1) and other cell lines (MCF-7, PANC1), they measured total and surface PD-L1 levels via Western blotting and flow cytometry.
  • Imaging: Confocal microscopy and immunofluorescence were used to track the co-localization of PD-L1 with markers for late endosomes (RAB7A), lysosomes (LAMP1), and recycling endosomes (RAB11).
  • In Vivo Models: They tested their findings in immunocompetent (BALB/c) and immunodeficient (nude) mice to confirm that the anti-tumor effects were indeed driven by the immune system (specifically CD8+ T cells).
  • Drug Screening: They identified AUY-922, an Hsp90 inhibitor, as a pharmacological agent capable of upregulating Hsc70.

Datasets

  • Clinical Data: The authors utilized the Kaplan-Meier Plotter database to correlate HSPA8 (Hsc70) expression levels with overall survival in breast cancer patients.
  • Proteomics Data: New LC-MS/MS datasets identifying PD-L1 and Hsc70 interacting partners were generated and deposited in the ProteomeXchange (PXD051281) and iProX (IPX0008562000) repositories.

Key Insights and Ideas

  • The Molecular Tug-of-War: Hsc70 and CMTM6 compete for the same binding site on PD-L1. When Hsc70 levels are high, it displaces CMTM6, preventing PD-L1 from recycling and instead pushing it toward the endolysosomal pathway.
  • eMI vs. CMA: While Hsc70 is famous for Chaperone-Mediated Autophagy (CMA), this study reveals that PD-L1 degradation occurs via endosomal microautophagy (eMI). This was proven using an Hsc70 mutant (3KA) that cannot bind to the endosomal membrane; this mutant failed to degrade PD-L1.
  • The TFG Bridge: The researchers identified TFG (TRK-fused gene) as a critical mediator that helps Hsc70 deliver PD-L1 to the degradation machinery.
  • Synergy with ICIs: Upregulating Hsc70 doesn't just work alone; it makes existing anti-PD-L1 and anti-CTLA4 therapies significantly more effective by reducing the "baseline" amount of PD-L1 the drugs have to contend with.

Key Results

  • PD-L1 Reduction: Overexpressing Hsc70 significantly decreased both total and surface PD-L1 protein levels without affecting its mRNA levels, confirming a post-translational degradation mechanism.
  • Tumor Suppression: In mouse models, Hsc70-overexpressing tumors were dramatically smaller than controls. This effect was absent in nude mice, proving the mechanism relies on an active immune response.
  • T-Cell Activation: Tumors with high Hsc70 showed a marked increase in infiltrating CD8+ T cells and Granzyme B+ (activated) cytotoxic T cells.
  • Pharmacological Proof-of-Concept: Treatment with AUY-922 increased Hsc70 expression, triggered PD-L1 degradation, and enhanced the efficacy of anti-PD-L1 therapy in vivo.

Limitations and Future Work

  • Model Specificity: Much of the in vivo work was performed in 4T1 breast cancer models in female mice. Further validation is needed across a broader range of "cold" tumors and different sexes.
  • Drug Toxicity: While AUY-922 showed promise, Hsp90 inhibitors have historically struggled in clinical trials due to off-target toxicities. Developing more specific Hsc70 inducers or TFG modulators might be a safer path forward.
  • Mechanism Granularity: While the role of eMI is clear, the exact "hand-off" between the Hsc70-TFG complex and the ESCRT machinery (which facilitates the inward budding of endosomes) remains an area for deeper structural biology exploration.

Summary updated

Abstract

Immune checkpoint inhibition targeting the PD-1/PD-L1 pathway has become a powerful clinical strategy for treating cancer, but its efficacy is complicated by various resistance mechanisms. One of the reasons for the resistance is the internalization and recycling of PD-L1 itself upon antibody binding. The inhibition of lysosome-mediated degradation of PD-L1 is critical for preserving the amount of PD-L1 recycling back to the cell membrane. In this study, we find that Hsc70 promotes PD-L1 degradation through the endosome-lysosome pathway and reduces PD-L1 recycling to the cell membrane. This effect is dependent on Hsc70-PD-L1 binding which inhibits the CMTM6-PD-L1 interaction. We further identify an Hsp90α/β inhibitor, AUY-922, which induces Hsc70 expression and PD-L1 lysosomal degradation. Either Hsc70 overexpression or AUY-922 treatment can reduce PD-L1 expression, inhibit tumor growth and promote anti-tumor immunity in female mice; AUY-922 can further enhance the anti-tumor efficacy of anti-PD-L1 and anti-CTLA4 treatment. Our study elucidates a molecular mechanism of Hsc70-mediated PD-L1 lysosomal degradation and provides a target and therapeutic strategies for tumor immunotherapy.
BibTeX
@inproceedings{xu2024hsc,
  author = {Xiaoyan Xu and Tingxue Xie and Mengxin Zhou and Yaqin Sun and Fengqi Wang and Yanan Tian and Ziyan Chen and Yanqi Xie and Ronghai Wu and Xufeng Cen and Jichun Zhou and Tingjun Hou and Lei Zhang and Chaoyang Huang and Qingwei Zhao and Dongrui Wang and Hongguang Xia},
  title = {{Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation}},
  booktitle = {Nature Communications},
  year = {2024},
  doi = {10.1038/s41467-024-48597-3},
}

Loading related content...

Figure